SVA SVA
Company Profile ↓Company Overview
SVA (SVA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Dec 2025 Revenue of $386.01M (+6.8% YoY); net profit $-59.68M.
- Trailing 12 Months Year-on-year growth — revenue +6.8%, earnings -165.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -36.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -36.29% |
| 1 Year: | 6.82% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -165.65% |
Stock Price Performance
| 1 Year: | - |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -36.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.49B | 470.17M | 361.37M | 386.01M |
| Cost of Revenue | - | 684.46M | 146.85M | 140.69M | 124.03M |
| Gross Profit | - | 808.30M | 323.32M | 220.69M | 261.98M |
| Operating Expenses | - | 1.27B | 928.58M | 695.94M | 549.27M |
| Operating Income | - | -460.85M | -605.26M | -475.26M | -287.29M |
| EBITDA | - | 183.10M | 81.19M | 162.01M | -151.25M |
| Interest Expense | - | 1.26M | 4.94M | 5.64M | 9.82M |
| Pretax Income | - | 25.24M | -84.49M | 42.84M | -262.10M |
| Tax Provision | - | -62.89M | 36.37M | 2.18M | -63.27M |
| Net Income | - | 113.87M | -13.49M | 90.91M | -59.68M |
| Diluted EPS | - | 1.00 | -0.19 | 1.27 | -0.83 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 14.11B | 13.66B | 12.34B | 8.54B |
| Current Assets | - | 12.13B | 11.83B | 10.64B | 7.06B |
| Cash & Equivalents | - | 4.28B | 1.27B | 335.27M | 488.25M |
| Inventory | - | 180.72M | 139.87M | 96.92M | 94.31M |
| Receivables | - | 497.01M | 426.01M | 300.89M | 286.34M |
| Total Liabilities | - | 1.40B | 1.64B | 2.04B | 2.15B |
| Current Liabilities | - | 1.09B | 1.15B | 1.45B | 1.54B |
| Long Term Debt | - | 11.51M | 177.82M | 163.84M | 265.48M |
| Total Debt | - | 74.67M | 298.98M | 391.32M | 505.62M |
| Total Equity | - | 8.92B | 8.71B | 8.26B | 4.44B |
| Shares Outstanding | - | 99.50M | 99.64M | 71.86M | 71.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -770.75M | 138.65M | -56.89M | -512.18M |
| Investing Cash Flow | - | -5.76B | -2.70B | 456.36M | 4.39B |
| Financing Cash Flow | - | -241.40M | -88.55M | -823.95M | -3.43B |
| Capital Expenditure | - | -403.37M | -156.21M | -97.59M | -49.12M |
| Free Cash Flow | - | -1.17B | -17.56M | -154.48M | -561.30M |
| Net Change in Cash | - | -6.77B | -2.65B | -424.48M | 441.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 54.1% | 68.8% | 61.1% | 67.9% |
| Operating Margin % | - | -30.9% | -128.7% | -131.5% | -74.4% |
| Net Margin % | - | 7.6% | -2.9% | 25.2% | -15.5% |
| ROE % | - | 1.3% | -0.2% | 1.1% | -1.3% |
| ROCE % | - | -3.5% | -4.8% | -4.4% | -4.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SVA
1Globe Capital Deadline Alert - TMX Newsfile
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPQy1YNFI2VEQ2SkpKR2JRb1Nyc2stYWpCajhob1FEY0szaUROWGV6RUw5WUc2UTl4b0w2QjFQMU45VkIzekl5d2phSTBPZW5hS0J1dXFmdkxEQTRmUkRoaWJRdm9fVVlJV0wtOHJ2QWNBd2NVMlRwY1lhWE1OWkQ4UjhFRENvZVFp?oc=5"…
Sinovac shareholders get until Dec. 31 to submit $55 dividend instructions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQUFdIVFMzR3pwV1JWdERqdmlpMmdKZHFMdnhSdkpOWHBTRFlsdm1VTzRIMzBVaElKOC1USnpoOXBpZnhsVEcweGdaNlZ2dHdKelVRLWF0YjlGS1g3d2xLN2taeDRhMFdaVGtHOVBRaGlWaTFUNlZ2ZC03M0VsX0wzb09KSnUtZFd3T3pSRn…
Sinovac Biotech, Ltd. Revenue Breakdown – NASDAQ:SVA - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1CQkxkMEtTS0VacTlmcFVqWlN6YW5rWlkwM2MtVjRZUTcwNndjU2ZPbVVobk5wa1Bra0swMDdwUzNDNm0zMG1yV0dDUHhqQWx6WmdmVlp5aHY4TnM4bmZPUE5qbk8wX05oSnlrUHRtTFIyTkpLTGc?oc=5" target="_blank">Sinovac …
Stock Score & Comprehensive Stock Analysis of Sinovac Biotech Ltd (SVA) - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5aVWxiZlpZQmdubnRueXVCU1c0TlE4N1VCdVg0Y19FWlNaVFhraERvbzZTSGNjdmh6VHl3cFhONEcxdFd4MTJ5X0VGbjFqd2s5SzExc1k0OXZOMWlFUmJOcDZURXZLRV9OMy1GNw?oc=5" target="_blank">Stock Score & Compreh…
Sernova Biotherapeutics Inc (TSE:SVA) Is Expected To Breakeven In The Near Future - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNZVM4R1E1OG1kWkphUmJQSUJCN19DZmdjTzl0OXNQRVBlSGVNOUZGWVNWbzhVcVMyemVTcDdLSUk0NjZTOE5GVUc1Wl93N1diYzVlb2JUM2dOc0NuVS1Pc3FwMUlpeHhjaFBIWEFVMHU3Ty01Y05SREphQ2tKeG11TUJTTFI0SXBMbW1kY2…
Sinovac regains compliance with Nasdaq listing requirements - Investing.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNa2t1TXFLX2VYZlgyYUFzR0dacmc1U2lUcC05QkFyalBQWGUwOUpsd1l1MGVhLWpVMlJLRzVscjFxMUZGMnFiWVdlZGhueGhpWHdjZ0pTVkpjc3VhakdQV2syQURUOFowWDJmcXNnRDVuUHJ4MnN5bkZKMzBJU3JQR3preWVyeXk1QVAtM3…
SVA — Frequently Asked Questions
What is the return on equity (ROE) of SVA?
SVA has a return on equity (ROE) of -1.34%. Its return on capital employed (ROCE) is -4.10%.
Is SVA a good stock to buy?
This page provides a data-driven analysis of SVA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.